☆ 4.2 Meeting Abstract

A Phase 1, First-in-Human Study of AMG 176, a Selective MCL-1 Inhibitor, in Patients With Relapsed or Refractory Multiple Myeloma

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)

Get Full Text
Add to Collection

Journal

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Volume 19, Issue 10, Pages E53-E54

Publisher

CIG MEDIA GROUP, LP
DOI: 10.1016/j.clml.2019.09.081

Keywords

Mcl-1 inhibitor; Pharmacokinetics; Tolerability

Categories

Oncology Hematology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.